Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]OP-801 is a hydroxyl dendrimer (HD) PET imaging agent labeled with fluorine‑18, designed to cross the blood-brain barrier and selectively target activated microglia and macrophages in regions of neuroinflammation. It enables visualization of neuroinflammatory processes with high specificity and sensitivity, making it a promising biomarker for diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, multiple sclerosis (MS), and Parkinson’s disease. The agent has demonstrated robust uptake in animal models of neurodegeneration, correlating with markers of activated microglia/macrophages. Clinical studies are ongoing to evaluate its safety, biodistribution, pharmacokinetics, and ability to detect neuroinflammation in humans[1][2][3][4][5][6][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]OP-801.